Shoulder Innovations Posts $7.05M Q3 Loss as Spending Outpaces Revenue
SI sits 87% above its 52-week low of $10.92.
Summary
Shoulder Innovations reported a $7.05M net loss for the third quarter, or 34c a share. That compares with a $10.0M operating loss in Q2, when revenue was $17.2M, up 56% year over year, on a 78.3% gross margin — so the loss is narrower than the prior quarter's operating figure, though the two measures aren't directly comparable. The company raised its 2026 revenue outlook to $68M–$70M. It is still burning cash while it funds a sales build-out and R&D, and it has a $300M shelf plus an 8.1M-share resale registration already on file from August, giving it a ready path to raise more equity if losses persist. The quarter follows the September FDA 510(k) clearance for the N-22 Humeral Head and an October limited user release of the InSet Go glenoid implant, both of which add near-term commercialization costs before they add revenue.
At the time of this announcement, SI was trading at $20.37 on NYSE in the Life Sciences sector, with a market capitalization of approximately $424.1M. The 52-week trading range was $10.92 to $24.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.